A new method for quickly sequencing microRNAs in cancer
Official title: A rapid method for global and targeted miRNA next generation sequencing
Funded at Claret Bioscience, LLC · NIH-10822035 · Data updated 2026-11-12
This study is working on a quick and easy way to analyze tiny RNA molecules that can change when someone has cancer, helping doctors detect the disease earlier and track how well treatments are working, which could lead to better care for patients.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Claret Bioscience, LLC NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | February 15, 2024 |
| Project end | February 14, 2026 |
| Funding year | 2024 |
| Award (this year) | $358,579 |
| NIH project number | 1R43HG013444-01 |
| Project ID | NIH-10822035 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with various types of cancer, particularly those undergoing treatment or monitoring for disease progression.
✕Less likely to help
Patients with non-cancerous conditions or those not currently undergoing treatment for cancer may not benefit from this research.
What this research studies
This research focuses on developing a rapid method for sequencing microRNAs (miRNAs), which are small RNA molecules that play a crucial role in regulating protein synthesis and are often altered in cancer. The approach, called miREALLY, aims to create a simple and efficient process for preparing miRNA samples for next-generation sequencing, allowing for better detection of subtle changes in miRNA profiles that can indicate disease progression or treatment response. By utilizing liquid biopsies, this method could enhance early cancer diagnosis and improve monitoring of treatment effectiveness, ultimately benefiting patient care.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and timely cancer diagnoses and improved monitoring of treatment responses, potentially enhancing patient survival rates.
How similar studies have gone: Previous studies have shown promise in using next-generation sequencing for miRNA profiling, indicating that this approach could build on existing successes in the field.
Where this research is happening
-
Claret Bioscience, LLC
Birmingham, United States Active
Researchers
- Principal investigator: Rao, Varsha — Claret Bioscience, LLC
- Study coordinator: Rao, Varsha
Related research
Other NIH-funded projects on the same topics.
-
A blood test that looks at DNA fragments and methylation to predict aggressive prostate cancer
A new blood-based test uses cfDNA fragment patterns and methylation to predict which prostate cancers may become high-risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.